

Amendments to the Claims:

The present listing of the claims replaces all past listings of the claims:

Listing of claims:

1. (Previously Presented) Pharmaceutical preparation, comprising at least one salt whose cationic component contains at least one representative from the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxycycline, oxytetracycline and rolitetracycline and whose anionic component contains at least one representative from the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate.
2. (Previously Presented) Pharmaceutical preparation pursuant to claim 1, comprising at least one salt of gentamicin-ibuprofen, gentamicin-naproxen, gentamicin-indomethacin, gentamicin-dexamethasone-21-phosphate, gentamicin-triamcinolone-21-phosphate, tetracycline-indomethacin, tetracycline-indomethacin, neomycin-indomethacin, clindamycin-indomethacin, streptomycin-naproxen, tetracycline-naproxen, clindamycin-naproxen, or streptomycin-ibuprofen.
3. (Currently Amended) Pharmaceutical preparation pursuant to claim 1, which is in the form of at least one member selected from the group consisting of ~~one~~ of molded bodies, tablets, powders, granules, fibers, knitted fabrics and fleece.
4. (Currently Amended) Pharmaceutical preparation pursuant to claim 1, which is part of a coating applied onto at least one member selected from the group consisting of ~~one~~ of molded bodies, powders, granules, fibers, knitted fabrics and fleece.
5. (Currently Amended) Pharmaceutical preparation, comprising a mixture in ~~the~~ a solid state of aggregation, which mixture is composed of at least one easily water soluble salt

of at least one of gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxycycline, oxytetracycline and/or rolitetracycline and at least one easily water soluble salt of at least one of ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and/or triamcinolone-21-sulfate and at least one inorganic and/or organic pharmaceutical adjuvant, and said pharmaceutical preparation has a shape of tablets and/or molded bodies.

6. (Currently Amended) Method for producing a pharmaceutical preparation pursuant to claim 3, comprising forming hardly water soluble antiphlogistic antibiotics salts ~~in tablet and/or molded body form through the effect of water or an aqueous environment on the tablets and/or molded bodies~~, wherein said salts form controlled-release antiphlogistic/antiphlogistics-antibiotic/antibiotics drugs.
7. (Currently Amended) Method for producing a pharmaceutical preparation pursuant to claim 5, comprising forming hardly water soluble antiphlogistic antibiotics salts ~~in tablet and/or molded body form through the effect of water or an aqueous environment on the tablets and/or molded bodies~~, wherein said salts form controlled-release antiphlogistic/antiphlogistics-antibiotic/antibiotics drugs.
8. (Currently Amended) A method of treating ~~an~~ a bacterial infection in a patient comprising administering a pharmaceutical preparation pursuant to claim 1 to said patient as a controlled-release antibiotics drug.
9. (Previously Presented) A permanent or temporary implant comprising the pharmaceutical preparation pursuant to claim 3.
10. (Previously Presented) A permanent or temporary implant comprising the pharmaceutical preparation pursuant to claim 5.

11. (New) A method for producing a pharmaceutical preparation according to claim 6, wherein said hardly water soluble antiphlogistic antibiotics salts are in tablet and/or molded body form.
12. (New) A method for producing a pharmaceutical preparation according to claim 7, wherein said hardly water soluble antiphlogistic antibiotics salts are in tablet and/or molded body form.

CONDITIONAL PETITION FOR EXTENSION OF TIME

If entry and consideration of the amendments above requires an extension of time, Applicants respectfully requests that this be considered a petition therefor. The Commissioner is authorized to charge any fee(s) due in this connection to Deposit Account No. 14-1263.

ADDITIONAL FEE

Please charge any insufficiency of fees, or credit any excess, to Deposit Account No. 14-1263.